Taiyo Pharma Co., Ltd.
Basic information
- Head office
- 14F, Marunouchi North Exit Building, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo 100-0005, Japan
- Chief executive
- Hina Iizuka
- Capital
- 450,000,000 (4 100 million)
- Employees (non-consolidated)
- Employees (consolidated)
- Start date
- 2017-08-02
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| 太陽インキ本社 |
Network
History
Establishment of Taiyo Pharma Co., Ltd.
Agreement with Chugai Pharmaceutical and Roche on the transfer of assets including manufacturing and sales approvals and manufacturing sales rights for 13 long-term listed products.
Transfer of manufacturing and sales approvals for Losifen®, Glycerol®, and Jigosin®.
Transfer of manufacturing and sales approvals for Resplen®.
Transfer of manufacturing and sales approvals for Bactramine®, Ribotriol®, Kaitril®, and Madpar®.
Transfer of manufacturing and sales approvals for Procarbazine hydrochloride, Furturon®, Oigulcon®, Pidoxarel®, and Chigason®.
Agreement with Japan B. Braun Ingelheim on the transfer of assets including manufacturing and sales approvals and manufacturing sales rights for Mexichil®.
Transfer of manufacturing and sales approvals for Mexichil®.
Agreement with AstraZeneca on the transfer of assets including manufacturing and sales approvals and manufacturing sales rights for four long-term listed products (Inderal®, Omeprazole®, Serocin®, and Tenomin®).
Transfer of manufacturing and sales approvals for Inderal® and Tenomin®.
Transfer of manufacturing and sales approvals for Omeprazole® and Serocin® (excluding injectable form).
Agreement with Janssen on the transfer of assets including manufacturing and sales approvals and manufacturing sales rights for one long-term listed product (Reminil®).
Transfer of manufacturing and sales approvals for Reminil®.
Establishment of a contract manufacturing company 'TAIYO Pharma Asia Co., Ltd.' in Thailand.
News
There is no news.
Public records
National Tax Agency basic information4010001185455
- Trade name
- 太陽ファルマ株式会社
- Trade name (kana)
- タイヨウファルマ
- Name in English
- Corporation type
- 301
- Address
- 〒100-0005 東京都千代田区丸の内１丁目６番５号
- Postal code
- 1000005
- Prefecture code
- 13
- City code
- 101
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2017-08-07
- Update date
- 2018-04-24
- Change date
- 2018-02-06
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 12
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 1725981
METI gBizINFO4010001185455
- Corporate number
- 4010001185455
- Trade name
- 太陽ファルマ株式会社
- Trade name (kana)
- タイヨウファルマ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 東京都千代田区丸の内１丁目６番５号
- Postal code
- 1000005
- Prefecture
- 東京都
- Prefecture code
- 13
- City or district
- 千代田区
- City code
- 101
- Street address
- 丸の内１丁目６番５号
- Organisation type
- 301
- Processing type
- 12
- Correction type
- 1
- Status
- Representative
- Capital
- Employees
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2018-04-24
- Key information
- 4010001185455